Pipeline
BIOGENERA SpA’s current pipeline reflects the company’s strong commitment to research in highly specialized areas with significant medical needs: cancer, metabolic disorders, and dermatological diseases. BIOGENERA SpA is actively developing multiple gene-specific molecules capable of revolutionizing treatments and improving patients’ lives.
Oncology
01
BGA002
GENE TARGET - MYCN
Research
Preclinical Development
Pathology
MYCN Positive Tumors
06
BGA008
GENE TARGET - BCL2
Research
Preclinical studies
Pathology
BCL2 Positive tumors
BCL2 Positive tumors
05
BGA007
PLK4 Positive Tumors
Research
Preclinical studies
Pathology
Tumori PLK4 positivi
04
BGA006
GENE TARGET - ALK
Research
Preclinical studies
Pathology
ALK Positive Tumors
ALK Positive Tumors
03
BGA005
GENE TARGET - SURVIVIN
Research
Preclinical studies
Pathology
Survivin positive tumors
Survivin positive tumors
02
BGA003
GENE TARGET - MYCN
Research
Preclinical studies
Pathology
Tumori MYC positivi
Dermatology and Metabolic Diseases
01
BGA011
Gene target – Dermatology
Research
Preclinical studies
Pathology
Confidential therapeutic
target
02
BGA012
Gene target – Metabolic disorder
Research
Preclinical studies
Pathology
Confidential therapeutic
target
English 
Italian